AVTR Stock Plunges Despite Q4 Earnings Beat Estimates, Margins Decline

Core Insights - Avantor, Inc. (AVTR) reported a fourth-quarter 2025 adjusted earnings per share (EPS) of 22 cents, a decrease of 18.5% year over year, but exceeded the Zacks Consensus Estimate by 4.8% [1] - The company's revenues for the quarter were $1.66 billion, down 1.4% year over year, yet surpassed the Zacks Consensus Estimate by 3% [2] - Despite beating estimates, shares of Avantor fell 13.6% following the earnings report [2][8] Revenue Details - Revenues of $1.66 billion reflected a 1.4% decline year over year, with a 4.1% organic sales decline after accounting for a positive foreign currency impact of 3.1% and a negative M&A impact of 0.4% [2] - The Laboratory Solutions segment reported net sales of $1.12 billion, down 0.9% year over year, with organic sales decreasing by 4.1% [3][4] Segment Analysis - The Laboratory Solutions segment showed mixed performance, with organic revenues declining 4% year over year, although there was modest sequential improvement [4] - The Bioscience Production segment's net sales were $547.5 million, down 2.4%, with organic sales also decreasing by 4.1% year over year [5][6] Margin Analysis - Avantor's gross profit declined 6.9% year over year to $523.9 million, with a gross margin contraction of 190 basis points to 31.5% [7] - Selling, general and administrative expenses increased by 5.7% year over year to $392.4 million, leading to an adjusted operating profit of $225.4 million, down 19.3% from the prior year [7] Financial Position - At the end of Q4 2025, Avantor had cash and cash equivalents of $365.4 million, up from $251.9 million at the end of Q3 2025, while total debt increased to $3.95 billion from $3.86 billion [9] 2026 Guidance - Avantor projects organic revenue growth to be between negative 2.5% and negative 0.5% for 2026, with adjusted EPS expected to range from 77 cents to 83 cents, below the Zacks Consensus Estimate of 89 cents [11][13] - The company anticipates that the VWR distribution business will modestly outperform Bioscience and Medtech Products, despite ongoing market pressures [11] Strategic Initiatives - Management emphasized a comprehensive "Avantor Revival" initiative aimed at operational improvement and sustainable growth, with significant investments planned to enhance operational efficiency and digital capabilities [16][17] - The company has achieved approximately $265 million in run-rate savings through cost discipline measures, although these have been partially offset by unfavorable mix and pricing actions [16]